An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium( EDNID): Protocol of a Randomized Controlled Trial

This investigator-initiated, randomized, controlled, superiority trial aims to assess the efficacy and safety of esketamine combined with dexmedetomidine for the management of agitation or delirium in intensive care unit (ICU) patients receiving non-invasive respiratory support. The primary endpoint is the duration of delirium.

Start Date02 Jun 2026

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

ChiCTR2600118814

/ Not yet recruitingNot ApplicableIIT

An Exploratory Study on the Short-Term Antidepressant Efficacy of Esketamine in Elderly Patients with Pre-Existing Depression Undergoing Knee Arthroplasty

Start Date01 Jun 2026

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

NCT07120477

/ Not yet recruitingPhase 4IIT

Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities

Suicide is one of the leading causes of early death worldwide. In Brazil, suicide rates have been rising steadily over the past two decades, and most suicides occur in low- and middle-income countries where access to specialized care is limited. There is an urgent need for fast-acting, practical interventions that can be delivered in public emergency settings. Two promising approaches have emerged: esketamine, a medication that can rapidly reduce suicidal thoughts within hours, and Crisis Response Planning (CRP), a brief session in which a trained clinician works with the person to create a personalized written plan for managing future suicidal crises.
The goal of this clinical trial is to learn if esketamine or Crisis Response Planning (CRP), each added to enhanced treatment as usual (eTAU), can prevent future suicide-related events compared to eTAU alone in adolescents and adults aged 14 years or older who recently attempted suicide or have severe suicidal thoughts. The main questions it aims to answer are:
Does a single esketamine infusion plus eTAU lower the risk of a new suicide-related event compared to eTAU alone over 12 months? Does a single session of Crisis Response Planning plus eTAU lower the risk of a new suicide-related event compared to eTAU alone over 12 months? Which approach leads to faster or more lasting improvements in suicidal thoughts, depression, anxiety, sleep, well-being, hopelessness, and quality of life? Are these interventions feasible, acceptable, and cost-effective within a public health system?
Researchers will compare three groups to see which approach works best to prevent suicide attempts, suicide-related hospitalizations, and suicide deaths over one year.
A total of 468 participants will be randomly assigned in equal numbers (156 per group) to one of three groups:
Esketamine group: receive a single intravenous esketamine infusion (0.50 mg/kg given over 40 minutes) in a monitored medical setting with continuous heart rate, blood pressure, and oxygen monitoring, plus eTAU. A physician will be present throughout. Participants will be observed for up to 24 hours before discharge.
Crisis Response Planning group: complete one 20-to-45-minute session with a trained clinician to build a personal crisis plan that includes warning signs, coping strategies, reasons for living, support contacts, and emergency resources. Participants will leave with a written and digital copy of their plan, plus eTAU.
Enhanced treatment as usual (eTAU) group: receive standard emergency care, safety counseling about access to lethal means, connection to the local mental health network (including Psychosocial Care Centers and primary care), and a scheduled psychiatric follow-up appointment within 7 days.
Participants will:
Complete health questionnaires about suicidal thoughts, depression, anxiety, sleep, well-being, hopelessness, and quality of life at 11 time points over one year (at enrollment, 24 hours, 7 days, 2 weeks, 4 weeks, 8 weeks, 16 weeks, 24 weeks, 32 weeks, 40 weeks, and 1 year) Provide a blood sample at the start of the study for exploratory analyses of biological markers that may be related to treatment response Use a smartphone app to report their mood, thoughts, and emotions four times a day for four weeks after enrollment Be monitored for safety and adverse events throughout the entire study period
The study takes place in the public emergency network of Indaiatuba, São Paulo, Brazil (population approximately 256,000), and is designed to reflect real-world clinical conditions. Participants who experience a new suicide-related event during the study will be offered an open-label rescue treatment combining esketamine and Crisis Response Planning, and will continue to be followed for the remainder of the year. The study also includes an evaluation of how well these interventions can be adopted and sustained within Brazil's public mental health system, including assessments of acceptability, feasibility, and cost-effectiveness.

Start Date01 May 2026

Sponsor / Collaborator

University of Sao Paulo

[+3]

100 Clinical Results associated with Esketamine Hydrochloride

100 Translational Medicine associated with Esketamine Hydrochloride

100 Patents (Medical) associated with Esketamine Hydrochloride

2,521

Literatures (Medical) associated with Esketamine Hydrochloride

31 Dec 2026·ANNALS OF MEDICINE

Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials

Review

Author: Qu, Shuangquan ; Wang, Jing ; Wu, Lei ; Tang, Ling ; Zhu, Yi ; Du, Zhen

BACKGROUND:

Postoperative nausea and vomiting (PONV) are significant perioperative challenges. This study evaluated the efficacy of perioperative esketamine in preventing PONV.

MATERIALS AND METHODS:

We systematically searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to August 2025 for randomized controlled trials investigating the effect of perioperative esketamine on PONV. The primary outcome was PONV incidence. Secondary outcomes included time to first flatus, postoperative pain degree, anxiety scores, agitation, anesthesia recovery time, and post-anesthesia care unit (PACU) stay duration. Data were analyzed using RevMan 5.4 and STATA 15.0 software. Sensitivity and subgroup analyses were performed to assess result stability and explore potential sources of heterogeneity.

RESULTS:

Thirty-eight randomized trials (3,425 patients) were included. Esketamine reduced the risk of nausea (RR=0.69, 95% CI: 0.53-0.90) and vomiting (RR=0.75, 95% CI: 0.57-0.98), shortened time to first flatus (SMD=-0.81, 95% CI: -1.48 to -0.15), and decreased rescue analgesic needs within 2 days (SMD=0.32, 95% CI: 0.2-0.5). However, it prolonged anesthesia recovery time (SMD=0.97, 95% CI: 0.28-1.67) and PACU stay (SMD=0.76, 95% CI: 0.27-1.26).

CONCLUSIONS:

Perioperative esketamine may reduce PONV and aid gastrointestinal recovery, but its potential to delay anesthesia recovery and PACU discharge requires consideration. Further studies are needed to clarify its risk-benefit profile.

DATE OF FIRST SUBMISSION TO PROSPERO:

10 March 2024.

DATE OF THE START OF STUDY SCREENING AGAINST ELIGIBILITY CRITERIA:

21 March 2024.

31 Dec 2026·ANNALS OF MEDICINE

Effects of nine sedative-analgesic combinations on fatigue after gastrointestinal endoscopy: a randomized controlled 3 × 3 factorial trial protocol

Article

Author: Huang, Lei ; Kuai, Ling-yu ; Liu, Lin-lin ; Gui, Wen-hu ; Lv, Jun ; Peng, Ke ; Ji, Fu-hai ; Xu, Li-na

INTRODUCTION:

Post-procedural fatigue is common after sedated gastrointestinal endoscopy and prolongs recovery. We describe a protocol for a prospective, single-center, randomized, controlled, 3 × 3 factorial trial to evaluate the effects of different sedative-analgesic combinations on patient-reported fatigue after gastrointestinal endoscopy.

PATIENTS AND METHODS:

Three hundred and fifteen patients (aged ≥ 45 years, ASA physical status I or II) presenting for gastrointestinal endoscopy with planned intravenous sedation will be randomly allocated (1:1:1:1:1:1:1:1:1; block sizes 9 and 18) to one of nine equip-sized groups generated by the factorial combination of three sedatives (propofol, ciprofol, remimazolam) with three adjuvant analgesics (sufentanil, esketamine, lidocaine). Sedation will be titrated to Modified Observer's Assessment of Alertness/Sedation scores of 1-2. The primary outcome is the Christensen Fatigue Scale score (range 1-10; higher = worse) 30 min after the procedure. The secondary outcome is the composite incidence of intra-procedural hypotension (mean arterial pressure < 65 mmHg) and hypoxemia (SpO₂ < 90% for ≥ 10 s). Primary analysis will employ two-way factorial ANOVA to test the main effects of sedatives and analgesics on the 30-min fatigue score, with an exploratory interaction analysis.

DISCUSSION:

The results of this trial will provide high-resolution evidence on which sedative or analgesic agent most effectively mitigates early post-endoscopy fatigue, thereby informing patient-centered sedation choices and enhancing recovery.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2500112657; registered on November 18, 2025).

31 Dec 2026·ANNALS OF MEDICINE

Letter to the editor regarding: Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials

Article

Author: Xia, Jia-yi ; Shen, Qi-hong

438

News (Medical) associated with Esketamine Hydrochloride

13 Apr 2026

·www.globenewswire.com

Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C.MALVERN, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that Optum/United Healthcare/United Behavioral Health (Optum/UHC/UBH) has updated its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy. Previously, this authority was limited to psychiatrists. The updated policy applies to PMHNPs operating in states where full practice authority (FPA) is granted and who are practicing within the advanced practice registered nurse state scope of practice. By expanding who can deliver TMS care, this policy update increases access to NeuroStar therapy amongst the 34.8 million Optum/UHC/UBH commercial covered lives. The policy update expands access to NeuroStar TMS therapy across 26 states and Washington, D.C., including Alaska, Arizona, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Maine, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Utah, Vermont, Washington, Wyoming, and the District of Columbia. “Nurse practitioners have long been on the front lines of mental healthcare, and this policy update by Optum/UHC/UBH is a significant milestone for expanding care across the country,” said Dan Reuvers, President and CEO of Neuronetics, Inc. “By recognizing the critical role that psychiatric mental health nurse practitioners play in delivering care, this decision will help ensure that more patients, particularly those in underserved communities, can access the life-changing treatment they deserve. We are proud of the work our dedicated health policy team has done to help make this possible.” Brian Banks, MSN, BSN, PMHNP-BC, owner of Lighthouse Mental Wellness in Pembroke, MA, applauds the advocacy efforts of Neuronetics' health policy team. “I have seen firsthand how effective NeuroStar TMS can be for patients who have not responded to medication,” said Brian Banks, MSN, BSN, PMHNP-BC. “This policy update is recognition that nurse practitioners are highly qualified to deliver this therapy, and it opens the door for so many more patients to get the help they need. I am proud to have been part of the journey that helped lead to this moment.” Major depressive disorder (MDD) is a serious condition that affects 21 million adults in the United States, with millions unable to tolerate or receiving inadequate relief from antidepressant medication.1 NeuroStar Advanced Therapy is a non-drug, non-invasive treatment option that delivers targeted magnetic pulses to stimulate neurons in the brain responsible for regulating mood. According to the NeuroStar Outcomes Database real-world study, patients achieved up to an 83% response rate and 62% remission rate of their MDD.2 Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates. For more information about NeuroStar TMS Therapy, please visit NeuroStar.com. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.3 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Neuronetics Contact:Investors:Mike Vallie or Mark KlausnerICR Healthcare443-213-0499ir@neuronetics.com Media:EvolveMKD646.517.4220NeuroStar@evolvemkd.com References1 https://www.nimh.nih.gov/health/statistics/major-depression 2 Outcomes Registry data was published by Sackeim HA, et al. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment.3 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

Clinical Result

07 Apr 2026

·www.globenewswire.com

Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions

New Platform Streamlines Path from Eligibility to Care for Patients Who Are Resistant to Standard TreatmentsSAN FRANCISCO, April 07, 2026 (GLOBE NEWSWIRE) -- Everbright Health, an AI-enabled services platform that helps mental health providers deliver advanced interventions as part of everyday care, announces its new platform to safely and effectively identify, engage, and manage care for patients who may be eligible for advanced mental health treatment options. This new, AI-enabled platform provides actionable data and insights to mental health providers about patients who may be eligible for advanced treatment options that can improve outcomes more than two-fold compared to medication and therapy alone. The platform aims to remove operational and administrative barriers to treatment options such as transcranial magnetic stimulation (TMS) and SPRAVATO® for patients with mental health conditions that are resistant to standard treatments. According to data from the National Institute of Health, nearly 60 million people in the U.S. live with a mental illness, and more than 15 million experience serious mental illness (SMI). Mental health care has historically relied on only medications and talk therapy to treat patients, but up to half of people with major mental health conditions don't get better through standard treatment options alone. For Everbright’s provider partners, the platform and specialized operational team help identify treatment-eligible patients, manage outreach and engagement, work through complex prior authorizations and billing workflows, and support the initiation and management of treatment, using proprietary AI technology and specialized human support. “More than a third of patients within the average mental health practice are eligible for advanced interventions like TMS and SPRAVATO®. But the majority of those people get missed by manual approaches for determining eligibility,” said Ben Kuhn, CEO of Everbright Health. “We use AI to navigate gaps in documentation, complex prior authorizations, and other administrative barriers that have prevented people with treatment-resistant conditions from receiving care that can be truly life-changing.” About Everbright Health Everbright Health enables mental health practices to bring advanced interventions into everyday care. The company embeds complete clinical programs – such as transcranial magnetic stimulation (TMS), SPRAVATO®, and others – into existing practices through a specialized AI-enabled services platform. Everbright provides all the infrastructure, technology, and operations required to launch, manage, and scale these programs successfully. Patients experience better outcomes, clinicians grow their practice with expanded care offerings, and payors see improved quality and lower costs – all among the millions of people with treatment resistance who need more from their mental health care. Everbright Health is a division of Careforce, Inc. For more information, visit www.everbrighthealth.com. Kate Stabrawakate@horseshoecommunications.com720-318-4080

07 Apr 2026

·www.globenewswire.com

Neuronetics Comments on Letter from Pointillist Family Office

MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company’s Board of Directors (the “Board”) from Jorey Chernett at Pointillist Family Office published on April 6, 2026: The Board and management team are committed to acting in the best interests of all shareholders and regularly evaluate opportunities to maximize shareholder value. The Board has reviewed Mr. Chernett’s letter and appreciates his engagement and dialogue as a shareholder. The Company agrees with Mr. Chernett that the current valuation does not fully reflect the strength of the Company’s business, and the Board is open to constructive engagement with its shareholders as the Company executes on its strategic priorities to enhance long-term value. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. “Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal years, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to maintain positive cash flow. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations. Investor Contact: Mike Vallie or Mark KlausnerICR Healthcare443-213-0499ir@neuronetics.com Media Contact: Devin BrodaICRDevin.Broda@icrinc.com References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

100 Deals associated with Esketamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10627	Esketamine Hydrochloride	N01AX14 N06AX27	DB11823

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	China	Janssen-Cilag International NV	17 Apr 2023
Major depressive disorder, moderate (MDD)	Australia	Janssen-Cilag Pty Ltd.	09 Mar 2021
Depressive Disorder, Major	European Union	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Iceland	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Liechtenstein	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Norway	Janssen-Cilag International NV	18 Dec 2019
Anesthesia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	18 Nov 2019
Depressive Disorder, Treatment-Resistant	United States	Janssen Pharmaceuticals, Inc.	05 Mar 2019
Pain	Germany	Pfizer Inc.	01 Aug 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Suicidal Ideation	Phase 3	United States	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Bulgaria	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Estonia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Germany	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Hungary	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Malaysia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Slovakia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Africa	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Korea	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Spain	Janssen Research & Development LLC	09 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02493868 (Pubmed \| Int J Psychiatry Clin Pract)	Phase 3	Psychotic Disorders	5,116	Esketamine	ydipstfswb(zqddxmmiqm) = fclymbobxs nbpopemfcv (wewgjamzha )	Negative	12 Feb 2026
				Esketamine	jkkzzzuwmq(mbiumkunvm) = ctlxgnpvka eosezntyoy (oqirlkjrqj )
NCT04860661 (Pubmed \| Eur J Anaesthesiol)	Not Applicable	Depression, Postpartum	322	Esketamine	bgmwdblxhv(blbievghbw) = Several mild central nervous events, such as dizziness (10.98%), hallucination (10.37%) and dissociation (5.49%), were observed during esketamine treatment. wmhhjrknqq (tsndlzuhhs ) View more	Positive	29 Jan 2026
				Saline
NCT07034963 (Pubmed \| Drug Des Devel Ther)	Phase 4	-	30	EsketamineRemifentanil + EsketamineRemifentaniline + EsketamineRemifentanil	utefjvmiqi(piffmmxqyh) = self-limiting dizziness (66.7%) ktleiwmwby (dkyhvvdxiv ) View more	Positive	01 Dec 2025
NCT05715671 (Pubmed \| Sleep Med)	Not Applicable	Dyssomnias	150	Esketamine loading dose 0.15 mg/kg plus maintenance dose 0.15 mg·kg^-1·h^-1	yvozxcvkaq(dclscfmgyu) = significantly higher plocttqvxc (znyndkfoue ) View more	Positive	01 Dec 2025
				Esketamine loading dose 0.3 mg/kg plus maintenance dose 0.3 mg·kg^-1·h^-1
NCT06608030 (Pubmed \| Pharmacol Res)	Phase 4	Depressive Disorder \| Anxiety Disorders	142	Esketamine	pxfhdnccpm(rohqrtbize) = gukndhogsm ubmdfsvlis (uuulhwuone ) View more	Positive	01 Dec 2025
				Saline	pxfhdnccpm(rohqrtbize) = tomswfebgi ubmdfsvlis (uuulhwuone ) View more
NCT05289050 (Pubmed \| J Pain Res)	Phase 4	-	144	S(+)-ketamine	fehjteudhy(crvvsrecla) = cmsxcujjwj mhqaqihffo (doeymjselg, 0.66) View more	Positive	01 Nov 2025
				0.9% sodium chloride solution	fehjteudhy(crvvsrecla) = opncqheafq mhqaqihffo (doeymjselg, 0.65) View more
NCT04829318 (ESCAPE-LTE, CTgov)	Phase 4	Depressive Disorder, Major	183	Esketamine (Esketamine Nasal Spray + Oral Antidepressant (AD))	lodojusjlz = euqucsfxvt yaetldnura (ocfoberqzn, xsyqioxwhd - eduykxgvor) View more	-	18 Sep 2025
				Esketamine (Esketamine + Oral AD)	uyhjakhhwo(asfrrhzaad) = pydjmgpcjl nsmhvqqljq (lvehrwbdfw, dndspdozvn - hkiuvxxywo) View more
Pubmed Manual	Not Applicable	Depressive Disorder	58,483	Esketamine Nasal Spray	qagzbjmrqo(bzrovwnlid) = sfhahgpygx qpebfajifi (ophredxyyp ) View more	Positive	10 Sep 2025
NCT04599855 (Pubmed \| JAMA Psychiatry) Manual	Phase 4	Depressive Disorder, Treatment-Resistant	378	esketamine 56 mg	wzdfaqnsgv(cjdiwaweel) = nausea (56 participants [24.8%]), dissociation (55 [24.3%]), dizziness (49 [21.7%]), and headache (43 [19.0%]). vypqocnrsf (zmaqdskqax )	Positive	02 Jul 2025
				esketamine 84 mg
NCT02782104 (SUSTAIN-3, Pubmed \| Int J Neuropsychopharmacol)	Phase 3	Depressive Disorder, Treatment-Resistant	1,148	Esketamine nasal spray + oral antidepressant	hxwjfcvych(gbihavbzti) = n = 3 fowybgturi (sfpiiaifiz ) View more	Positive	06 Jun 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis